GSK Plc experienced a decrease in vaccine sales during the third quarter, which had a negative impact on its overall profit despite strong performance in other areas.

Sales of the respiratory syncytial virus vaccine, Arexvy, were £188 million ($245 million), falling short of the analysts' forecast of £290 million.

The shingles vaccine, Shingrix, generated £739 million in sales, significantly below the expected £895 million.

The lower sales figures have been attributed to access issues in the U.S. market, causing concerns among investors about the future performance of these important products.